In a fast-paced pharmaceutical industry, the race to develop new drugs is being accelerated by innovative AI technologies. However, the critical task of documenting these advancements has struggled to keep up. Enter Biolevate, a Paris-based startup that has raised €6 million in seed funding to transform medical writing with the power of artificial intelligence.
Founded by longtime friends Joel Belafa and Nathan Chen, Biolevate is addressing a pressing need in the biotech sector. As the pace of drug development quickens, the administrative burden on pharmaceutical companies to create regulatory documentation has reached new heights. Belafa, who previously worked at French AI unicorn Dataiku, and Chen, with expertise from Danish healthcare company Coloplast, recognized this challenge and set out to build a solution.
Biolevate’s platform, known as Elise, utilizes natural language processing (NLP) and computer vision to assist medical writers in the creation and management of research and compliance documents. By guiding writers through the materials and reducing the time and effort needed to understand or correct the content, Biolevate aims to streamline the writing process and help their clients stay ahead of the rapid pace of innovation.
“There’s a significant opportunity in making medical writing more efficient using AI, and the team at Biolevate offers an impressive solution to transform medical documentation processes into a seamless and effective procedure that supports innovation and drives scientific breakthroughs benefiting society,” said Julien Hobeika, Partner at lead investor EQT Ventures.
With the fresh €6 million in seed funding, Biolevate plans to further develop its AI-powered platform and expand its reach within the pharmaceutical industry. As the biotech sector continues to push the boundaries of drug development, Biolevate is poised to be a crucial ally in ensuring that the accompanying documentation keeps up with the breakneck pace of progress.
